Aurinia Pharmaceuticals Inc. (AUPH) Return on equity 2018–2025
Aurinia Pharmaceuticals Inc. (AUPH) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
49.4%FY2025 · since FY2018: -39.1% → 49.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 49.4% | +47.9 pp |
| FY2024 | 1.5% | +22.2 pp |
| FY2023 | -20.6% | +6.0 pp |
| FY2022 | -26.7% | +11.1 pp |
| FY2021 | -37.8% | -12.6 pp |
| FY2020 | -25.2% | +4.4 pp |
| FY2019 | -29.6% | +9.5 pp |
| FY2018 | -39.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AUPH financial trends
AUPH RevenueAUPH Net incomeAUPH Net marginAUPH Gross profitAUPH Gross marginAUPH Operating incomeAUPH Operating marginAUPH Operating cash flowAUPH Free cash flowAUPH Capital expendituresAUPH Stock buybacksAUPH Dividends paidAUPH Total assetsAUPH Total liabilitiesAUPH Shareholders’ equityAUPH overview →